

# NEXT SCIENCE®

## Update on Irrimax complaint

**Sydney, Australia Monday, 30 August 2021**, Next Science Limited (ASX:NXS) (**Next Science**) advises that further to Next Science's announcement on 27 August 2021, Irrimax Corporation has now served on Next Science its complaint in the United States District Court for the Northern District of Georgia alleging common law unfair competition and false advertising regarding XPerience™.

Next Science stands by the independently verified performance of XPerience™, strenuously denies the allegations made in, and will vigorously defend, the complaint.

Approved and authorised for release by Next Science's Managing Director.

Further information:

**Judith Mitchell**

Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

**Michael Brown**

Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

### About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: [www.nextscience.com](http://www.nextscience.com).

**Next Science Limited ACN 622 382 549**

Suite 1902, Level 19, Tower A, The Zenith, 821 Pacific Highway, Chatswood NSW 2067  
[www.nextscience.com](http://www.nextscience.com)